George Eric Davis Sells 1,850 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP George Eric Davis sold 1,850 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $85.01, for a total value of $157,268.50. Following the completion of the sale, the executive vice president now owns 56,157 shares of the company’s stock, valued at approximately $4,773,906.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

George Eric Davis also recently made the following trade(s):

• On Thursday, March 28th, George Eric Davis sold 24,602 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $88.34, for a total transaction of $2,173,340.68.

BioMarin Pharmaceutical Stock Down 0.9 %

BioMarin Pharmaceutical stock opened at $81.83 on Thursday. BioMarin Pharmaceutical Inc. has a fifty-two week low of $76.02 and a fifty-two week high of $99.56. The firm has a market capitalization of $15.54 billion, a price-to-earnings ratio of 76.48, a price-to-earnings-growth ratio of 1.30 and a beta of 0.34. The stock’s fifty day moving average is $86.56 and its two-hundred day moving average is $89.02. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.70 and a current ratio of 2.74.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm had revenue of $646.21 million during the quarter, compared to the consensus estimate of $639.53 million. BioMarin Pharmaceutical had a net margin of 8.31% and a return on equity of 5.34%. The firm’s revenue for the quarter was up 20.2% on a year-over-year basis. During the same period last year, the firm posted $0.11 EPS. Analysts predict that BioMarin Pharmaceutical Inc. will post 1.98 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on BMRN shares. Cantor Fitzgerald restated an “overweight” rating and issued a $110.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, April 25th. Royal Bank of Canada reissued a “sector perform” rating and issued a $100.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Wells Fargo & Company increased their price target on BioMarin Pharmaceutical from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Morgan Stanley dropped their price objective on shares of BioMarin Pharmaceutical from $115.00 to $112.00 and set an “overweight” rating on the stock in a research note on Friday, April 26th. Finally, Scotiabank raised their target price on shares of BioMarin Pharmaceutical from $83.00 to $85.00 and gave the stock a “sector perform” rating in a research note on Thursday, April 25th. Seven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $107.50.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. KB Financial Partners LLC increased its position in BioMarin Pharmaceutical by 51.3% during the third quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company’s stock worth $31,000 after buying an additional 118 shares in the last quarter. Lindbrook Capital LLC increased its position in BioMarin Pharmaceutical by 259.8% during the 4th quarter. Lindbrook Capital LLC now owns 385 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 278 shares in the last quarter. Castleview Partners LLC purchased a new position in BioMarin Pharmaceutical in the 3rd quarter valued at about $35,000. Benjamin F. Edwards & Company Inc. boosted its stake in shares of BioMarin Pharmaceutical by 135.3% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 249 shares during the last quarter. Finally, Jones Financial Companies Lllp purchased a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth about $43,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.